Current Cardiology Reports

, Volume 4, Issue 5, pp 388–395

Ventricular tachycardia in structurally normal hearts

  • T. Scott Wall
  • Roger A. Freedman
Article

Abstract

This review focuses on four distinct syndromes of ventricular tachycardia that occur in the structurally normal heart. Recent advances in the fields of molecular biology and genetics, along with intracardiac mapping techniques, have led to a greater understanding of the underlying mechanisms of and therapeutic options for these syndromes. The cyclic AMP-mediated triggered activity tachycardias, including exercise-induced right ventricular outflow track tachycardia and repetitive monomorphic ventricular tachycardia, are the most common of these syndromes. Idiopathic left ventricular tachycardia, for which there is significant evidence for re-entry within the Purkinje network, is largely curable with catheter ablation. The long QT syndrome comprises a heterogeneous group of ion channel defects leading to prolongation of myocyte repolarization and Torsade de Pointes ventricular tachycardia. Brugada syndrome, a familial disorder of transmembrane ion transport, is felt to be the result of a group of sodium channel defects leading to characteristic electrocardiographic abnormalities, and syncope and sudden death. Primary focus is given to recent advances in our understanding of the underlying mechanism and current therapeutic approaches.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lerman BB: Ventricular arrhythmias in normal hearts. Cardiol Clin 2000, 18:265–291, vii. An up-to-date review of both adenosine-sensitive (RVOT) ventricular tachycardia and idiopathic LV tachycardia, including discussions of current understanding of the underlying mechanisms of tachycardia and current therapeutic approaches.PubMedCrossRefGoogle Scholar
  2. 2.
    Lerman BB: Mechanism of repetitive monomorphic ventricular tachycardia. Circulation 1995, 92:421–429.PubMedGoogle Scholar
  3. 3.
    Markowitz SM: Adenosine-sensitive ventricular tachycardia. Right ventricular abnormalities delineated by magnetic resonance imaging. Circulation 1997, 96:1192–1200.PubMedGoogle Scholar
  4. 4.
    Globits S: Significance of morphological abnormalities detected by MRI in patients undergoing successful ablation of right ventricular outflow tract tachycardia. Circulation 1997, 96:2633–2640.PubMedGoogle Scholar
  5. 5.
    Krebs ME: Ventricular tachycardias mimicking those arising from the right ventricular outflow tract. J Cardiovasc Electrophysiol 2000, 11:45–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Ouyang F: Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol 2002, 39:500–508. An investigation of approaches to the electrocardiographic characterization of adenosine-sensitive tachycardias that originate from the RVOT versus those from the LV below the aortic sinus cusp.PubMedCrossRefGoogle Scholar
  7. 7.
    Callans DJ: Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol 1997, 29:1023–1027. Investigation of a series of patients with either RVOT tachycardia or LVOT tachycardia with characterization of ECG criteria to aid in the diagnosis. Tachycardias with a precordial R-wave transition at or before V2 were consistent with a left-sided origin.PubMedCrossRefGoogle Scholar
  8. 8.
    Yeh SJ: Adenosine-sensitive ventricular tachycardia from the anterobasal left ventricle. J Am Coll Cardiol 1997, 30:1339–1345.PubMedCrossRefGoogle Scholar
  9. 9.
    Lerman BB: Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation 1986, 74:270–280.PubMedGoogle Scholar
  10. 10.
    Lerman BB: Right ventricular outflow tract tachycardia due to a somatic cell mutation in G protein subunit ai2. J Clin Invest 1998, 101:2862–2868.PubMedCrossRefGoogle Scholar
  11. 11.
    Morady F: Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation 1990, 82:2093–2099.PubMedGoogle Scholar
  12. 12.
    Blanck Z: Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol 1993, 4:253–262.PubMedCrossRefGoogle Scholar
  13. 13.
    Gaita F: Idiopathic verapamil-responsive left ventricular tachycardia: clinical characteristics and long-term follow-up of 33 patients. Eur Heart J 1994, 15:1252–1260.PubMedGoogle Scholar
  14. 14.
    Maruyama M: Demonstration of the reentrant circuit of verapamil-sensitive idiopathic left ventricular tachycardia: direct evidence for macroreentry as the underlying mechanism. J Cardiovasc Electrophysiol 2001, 12:968–972.PubMedCrossRefGoogle Scholar
  15. 15.
    Ouyang F: Electroanatomic substrate of idiopathic left ventricular tachycardia: unidirectional block and macroreentry within the purkinje network. Circulation 2002, 105:462–469. Three-dimensional electroanatomic mapping technique was used in a series of patients with idiopathic LV tachycardia to demonstrate an abnormal potential within the posterior Purkinje system during sinus rhythm. The earliest abnormal potential was critical for the tachycardia circuit and predicted successful ablation.PubMedCrossRefGoogle Scholar
  16. 16.
    Okumura K, Matsuyama K, Miyagi H, et al.: Entrainment of idiopathic ventricular tachycardia of left ventricular origin with evidence for reentry with an area of slow conduction and effect of verapamil. Am J Cardiol 1988, 62(10 Pt 1):727–732.PubMedCrossRefGoogle Scholar
  17. 17.
    Tsuchiya T: Effects of verapamil and lidocaine on two components of the re-entry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol 2001, 37:1415–1421.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakagawa H: Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation 1993, 88:2607–2617.PubMedGoogle Scholar
  19. 19.
    Betts TR: Radiofrequency ablation of idiopathic left ventricular tachycardia at the site of earliest activation as determined by noncontact mapping. J Cardiovasc Electrophysiol 2000, 11:1094–1101.PubMedCrossRefGoogle Scholar
  20. 20.
    Gill JS, Blaszyk K, Ward DE, Camm AJ: Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J 1993, 126:1126–1133.PubMedCrossRefGoogle Scholar
  21. 21.
    Khan IA: Long QT syndrome: diagnosis and management. Am Heart J 2002, 143:7–14. A recent review of both congenital and acquired (drug-induced) long QT syndrome.PubMedCrossRefGoogle Scholar
  22. 22.
    Splawski I: Spectrum of mutations in long QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000, 102:1178–1185. An investigation outlining the large number of novel mutations found in a group of unrelated patients with congenital long QT syndrome.PubMedGoogle Scholar
  23. 23.
    Mitcheson JS: A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000, 97:12329–12333. An investigation outlining a possible structural explanation for the multitude of commonly used medications cause acquired long QT syndrome by blockade of the HERG IKr channel, whereas other similar ion channels are far less commonly affected.PubMedCrossRefGoogle Scholar
  24. 24.
    Tzivoni D: Treatment of torsade de pointes with magnesium sulphate. Circulation 1988, 77:392–397.PubMedGoogle Scholar
  25. 25.
    Baile DS: Magnesium suppression of early after depolarizations and ventricular arrhythmias induced by caesium in dogs. Circulation 1988, 77:1395–1402.Google Scholar
  26. 26.
    Zareba W: Influence of genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998, 339:960–965. The total number of adverse events in patients with a HERG or KVLQT1 mutation associated with the long QT syndrome was higher than patients with a SCN5A mutation. However, patients with a SCN5A mutation were more likely to have a fatal event.PubMedCrossRefGoogle Scholar
  27. 27.
    Vincent GM: The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome. N Engl J Med 1992, 327:846–852.PubMedCrossRefGoogle Scholar
  28. 28.
    Moss AJ: Effectiveness and limitations of beta-blocker therapy in congenital long QT syndrome. Circulation 2000, 101:616–623.PubMedGoogle Scholar
  29. 29.
    Eldar M: Permanent cardiac pacing in patients with the long QT syndrome. J Am Coll Cardiol 1987, 10:600–607.PubMedCrossRefGoogle Scholar
  30. 30.
    Moss AJ: Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation 1991, 84:1524–1529.PubMedGoogle Scholar
  31. 31.
    Eldar M: Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol 1992, 20:830–837.PubMedCrossRefGoogle Scholar
  32. 32.
    Schwartz PJ: Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome: a world-wide report. Circulation 1991, 84:503–511.PubMedGoogle Scholar
  33. 33.
    Schwartz PJ: Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na channel blockade and to increases in heart rate: implications for gene specific therapy. Circulation 1995, 92:3381–3386.PubMedGoogle Scholar
  34. 34.
    Compton SJ: Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996, 94:1018–1022.PubMedGoogle Scholar
  35. 35.
    Brugada P: Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992, 20:1391–1396.PubMedCrossRefGoogle Scholar
  36. 36.
    Brugada J: Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol 1997, 8:325–331.PubMedCrossRefGoogle Scholar
  37. 37.
    Naccarelli GV: The Brugada syndrome. Curr Opin Cardiol 2002, 17:19–23. A recent review of the Brugada syndrome covering diagnostic and therapeutic approaches, as well as the current understanding of the underlying pathophysiology.PubMedCrossRefGoogle Scholar
  38. 38.
    Viskin S: Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls. Heart 2000, 84:31–36.PubMedCrossRefGoogle Scholar
  39. 39.
    Bezzina C: A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res 1999, 85:1206–1213.PubMedGoogle Scholar
  40. 40.
    Rivolta I: Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. J Biol Chem 2001, 276:30623–30630.PubMedCrossRefGoogle Scholar
  41. 41.
    Yasuda M: ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs. Heart 2001, 85:E3.PubMedCrossRefGoogle Scholar
  42. 42.
    Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996, 27:1061–1070.Google Scholar
  43. 43.
    Krishnan SC: ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol 1998, 9:1167–1172.PubMedCrossRefGoogle Scholar
  44. 44.
    Brugada P: Prognostic value of electrophysiologic investigations in Brugada syndrome. J Cardiovasc Electrophysiol 2001, 12:1004–1007. Inducibility of a sustained ventricular arrhythmia was a predictor of adverse outcome in both symptomatic and asymptomatic patients with Brugada syndrome.PubMedCrossRefGoogle Scholar
  45. 45.
    Chen Q: Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998, 392:293–294.PubMedCrossRefGoogle Scholar
  46. 46.
    Rook MB: Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res 1999, 44:507–517.PubMedCrossRefGoogle Scholar
  47. 47.
    Brugada P: Sudden death in patients and relatives with the syndrome of right bundle branch block, ST segment elevation in the precordial leads V(1)to V(3)and sudden death. Eur Heart J 2000, 21:321–326.PubMedCrossRefGoogle Scholar
  48. 48.
    Ikeda T: Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification. J Am Coll Cardiol 2001, 37:1628–1634. A comparison of the uses of various noninvasive markers for detecting risk of life-threatening arrhythmic events in patients with Brugada syndrome. T-wave alternans and QT dispersion were not predictive of risk, but late potentials on signal-averaged ECG had the most significant correlation with life-threatening events when compared with controls.PubMedCrossRefGoogle Scholar
  49. 49.
    Takenaka S: Relatively benign clinical course in asymptomatic patients with brugada-type electrocardiogram without family history of sudden death. J Cardiovasc Electrophysiol 2001, 12:2–6. Asymptomatic patients with Brugada syndrome without a family history of sudden death were studied. None of the 11 patients followed for a mean of 43 months had a life-threatening arrhythmic event, suggesting a more benign course in these patients.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • T. Scott Wall
    • 1
  • Roger A. Freedman
    • 1
  1. 1.Division of CardiologyUniversity of Utah Medical CenterSalt Lake CityUSA

Personalised recommendations